86% Cancer Cure in Clinical Trials.

[Guest guest]

From: jean-wally@... ( & Wally)

Date sent: Mon, 16 Jul 2001 14:21:28 -0700 (PDT)

moonbeam@...

Subject: Re: Cancer Drink

>I have just been on the list a few days.. My husband has adrenal cancer

>in the liver and it is inoperable. What kind of cancer do you have? We

>need help.

> Please send me the information you are talking about 86% cure

> rate...Jean

Hi,

Firstly, if I had cancer then I probably would have only recently

begun researching cancer and hence my knowledge would be limited.

Unfortunately several of my friends had to die from cancer while I

spent many years trying to find a solution to the cancer problem. These days my

friends

recover from cancer.

Medicine is an evidenced based science. There is plenty of patient

derived evidence from clinical trials to prove that direct injection of tumors

can

resolve the tumor - as can direct electrical curent applied into the tumor mass.

Such a process could see General Practioners curing many cancers in

their surgeries in a one hour non invasive, harmless procedure.

Of course that would be very expensive, as it would cost drug companies

billions of dollars in lost drug sales. So there would be a lot of opposition to

such

treatment.

If I had a big single tumor I would try and get ultrasound guided hot

saline/ethanol injections directly into the tumor to reduce the size of the

primary tumor

by 90% or more then use the activated immune sytem to clean up what was

left and prevent further metastasis.

References on injections of tumors..... quote... " 86% complete remmision "

of cancer in clinical trials.

1: Rays 1999 Apr-Jun;24(2):348-57

Percutaneous ethanol injection of autonomously functioning thyroid nodule.

Solbiati L, Ierace T, Cova L, Dellanoce M, Marelli P.

Servizio di Radiologia, Ospedale Civile di Busto Arsizio, Italy.

Percutaneous ethanol injection (PEI) is proposed for treatment of

autonomously

functioning thyroid nodule, especially for small-mid-sized solitary

nodules, for patients refusing the other methods or not proving responsive

to radioiodine, or for patients with non toxic nodule. The injection is

performed under color Doppler sonography guidance, evaluating the most

vascularized areas of the tumor where to primarily inject ethanol solution

with 21-22 gauge needles.

Complete remission was achieved by different authors in 86% of cases and

the efficacy of response was shown to be inversely proportional to the nodule

volume.

When TSH remains undetectable, a second cycle of PEI can be performed. If

there is complete lack of blood flow signals on color or power Doppler

with persisting thyroid hyperfunction, sonographic contrast media can be

administered i.v. to assess residual areas of intranodal hypervascularity.

Disappearance of nodular hypervascularity at color Doppler sonography and

complete normalization of the scintigraphic pattern is usually observed in

all cases.

PEI is generally well tolerated; no recurrences of the disease and no

cases of

hypothyroidism have been reported.

PMID: 10509136 [PubMed - indexed for MEDLINE]

-------------------------------------------------------

3: Radiol Med (Torino) 1998 Sep;96(3):238-42

[ultrasonography-guided percutaneous ethanol injection in large an/or

multiple liver metastasis].

[Article in Italian]

Giorgio A, Tarantino L, Mariniello N, De Stefano G, Perrotta A, Aloisio V,

Del Viscovo L, Alaia A.

Servizio di Ecografia ed Ecointerventistica, Ospedale D. Cotugno, Napoli.

assanui@...

INTRODUCTION: Percutaneous ethanol injection (PEI) under sonographic

guidance is an effective therapy for hepatocellular carcinoma on

cirrhosis, while less favorable results have been reported for liver

metastases. Surgery and/or other new treatments (i.e., interstitial

thermotherapy) are indicated only for small metastases (< 3 cm) and

surgeons no longer perform the palliative debulking of neoplastic masses.

PATIENTS AND METHODS: From March, 1994, to December, 1997, thirty-three

patients with 62 large (> 3.5 cm) and/or multiple liver metastases, who

were not eligible for surgery nor thermotherapy, were treated with

one-shot PEI under general anesthesia. The diameter of the nodules ranged

35-92 mm (mean: 39); the lesions were single in 15 patients and localized

in both the right and the left lobe in 19 patients. 25-110 ml ethanol were

injected per session. Post-treatment results were assessed with dynamic or

dual-phase spiral CT; therapeutic success was defined as the absence of

hyperdense lesion areas. RESULTS: Complete necrosis of the metastases was

shown in 10 patients (30.3%). Necrosis rate ranged 70-90% in 21 patients

(64%) and was 50% in 2 patients (5.7%). Survival rates were 94%, 80%, 80%

and 44% at 12, 24, 36 and 44 months, respectively. No major complications

were observed. Seeding of neoplastic cells along the needle tract has been

never observed to date. DISCUSSION: Metastasis diameter and number impact

on long-term survival. PEI under general anesthesia allows to treat also

the patients who are not eligible for other treatments and to inject large

amounts of ethanol per session in different tumor areas because metastases

usually set on in an otherwise healthy liver. CONCLUSIONS: One-shot PEI

can cause major, even complete, tumor necrosis in large and multiple liver

metastases. The absence of any important complications and the survival

rates in our series seem to indicate that one-shot PEI is effective for

tumor debulking in patients not eligible for surgery and other alternative

treatments.

Publication Types:

Clinical trial

PMID: 9850718 [PubMed - indexed for MEDLINE]

----------------------------------------------------------

4: Nippon Igaku Hoshasen Gakkai Zasshi 1998 Jun;58(7):366-8

[Experimental study of percutaneous hot ethanol injection therapy (PHEIT)

by continuous heating device for hepatocellular carcinoma].

[Article in Japanese]

Kawai N, Sato M, Sonomura T, Kishi K, Terada M, Tanaka K, Tanaka H, Nosaka

M, Takata H, Nakanishi H, Yoshikawa A.

Department of Radiology, Wakayama Medical College.

Percutaneous ethanol injection therapy (PEIT) is widely used as a local

treatment for hepatocellular carcinoma (HCC). However, because only a

small amount of ethanol can be used in one PEIT session and because the

antitumor effect is limited, this modality is indicated only when there

are three or fewer tumors and when the tumor diameter is < or = 3 cm. To

obtain a more potent and certain antitumor effect, we have devised a new

treatment called percutaneous hot ethanol injection therapy (PHEIT), and

developed a Continuous Heating Device with which ethanol can be heated and

locally injected at a specified temperature. The continuous Heating Device

is composed of three major components: a syringe heater, a needle

thermocontroller, and a needle tip thermosensor. A disposable syringe

filled with liquid is inserted into the syringe heater, which heats the

liquid to a desired temperature by adjusting the voltage. The needle

thermocontroller is a puncture guide needle to which a heating device has

been attached. The needle-tip thermosensor constantly measures, displays

and records the temperature of the liquid at the needle tip during

injection. Also, because the Continuous Heating Device is a closed-circuit

system, there is no risk of accidental a fire, which ensures procedural

safety. It is also possible to use this device to safely heat and inject a

variety of other liquids, such as physiological saline and anticancer

agents and thus contribute to the widespread development of

ultrasound-guided injection therapy.

PMID: 9711077 [PubMed - indexed for MEDLINE]

----------------------------------------------------

5: Eur Radiol 1996;6(4):494-501

A modified technique for ethanol injection of liver tumors: preliminary

results.

Elgindy NM, Lindholm HB, Gunven PM, Ohlsen HL.

Department of Diagnostic Radiology, Karolinska University Hospital,

Stockholm, Sweden.

The technique for ethanol injection of liver tumors was modified in order

to obtain less reflux with a better intratumoral distribution of ethanol,

leading to more extensive necrosis and to a reduction of pain. The needle

was stopped just before its entrance into the tumor and ethanol was

injected while the needle was advanced a little beyond the distant border

of the tumor. Pain and change in echogenicity during and immediately after

each injection were evaluated in 11 patients with 38 malignant lesions who

received 90 injections with the new or 46 with the conventional technique.

Computed tomography and biopsies were used for later follow-up. With the

new technique the injected tissue volume converted much more markedly to

high echogenicity (p < 0.005), the pain was significantly reduced (p <

0.001), and posttreatment biopsies significantly less often contained

viable cells (p < 0.05). These preliminary results suggest that the

modified injections were more effective and less painful, and have enabled

us to inject a larger volume of ethanol at each session to reduce the

number of treatments.

PMID: 8798031 [PubMed - indexed for MEDLINE]

------------------------------------------------

6: Radiology 1994 Jan;190(1):53-7

Comment in:

Radiology. 1994 Jul;192(1):284

Percutaneous hot saline injection therapy for hepatic tumors: an

alternative to percutaneous ethanol injection therapy.

Honda N, Guo Q, Uchida H, Ohishi H, Hiasa Y.

Department of Radiology, Nara Medical University, Japan.

PURPOSE: To evaluate the usefulness of percutaneous hot saline injection

therapy (PSIT) in the treatment of hepatocellular carcinoma (HCC).

MATERIALS AND METHODS: Twenty patients with HCC (23 nodules) underwent

PSIT. Mean tumor diameter was < or = 30 mm. PSIT was performed by

injecting hot saline into the HCC. The therapeutic effect of PSIT was

evaluated with computed tomography, angiography, measurement of

alpha-fetoprotein levels, and histopathologic examination of needle biopsy

and resected specimens. RESULTS: No complications were encountered, and a

therapeutic effect was obtained in all cases. When the injected material

cools, it becomes physiologic saline making it possible to inject

relatively large volumes in a single session. CONCLUSION: PSIT has promise

as a form of curative local therapy for small HCCs and is expected to

exert a safe and favorable therapeutic effect on large HCCs as well.

PMID: 8259428 [PubMed - indexed for MEDLINE]

------------------------------------

7: Radiol Med (Torino) 1993 Apr;85(4):462-6

[Treatment of Plummer's adenoma: correlation between

ultrasonography-guided percutaneous injection of ethanol and

autoimmunity].

[Article in Italian]

Argalia G, Migliorini D, Salvolini L, Macellari L, Giuseppetti GM,

Morosini PP, Arnaldi G, Vecchi A, Gusella P.

Istituto di Semeiologia, Diagnostica e Terapia Strumentale, Universita

degli Studi di Ancona.

The authors investigated the value of percutaneous ethanol injection in

the treatment of Plummer's adenoma. Ten patients were studied: they

exhibited a single, hot and toxic nodule in the thyroid. Thyroid

autoimmunization (TSAb; TMAb; TGAb) and function (T3; T4; TSH; FT3; FT4)

were studied in all patients, before treatment and at 1 month and 3

months. Scintigraphy with 99Tc was performed at the same time intervals.

In the euthyroid stage, alcoholization was preceded by US and cytology.

Three-four ml of ethanol 95 degrees were injected once or twice a week,

from a minimum of 3 to a maximum of 8 injections. Treatment was successful

in 2 cases; partial success was obtained in 4 cases, and in 4 cases

treatment failed. In all successful cases antibodies were negative and the

nodules had hypoechoic echostructure, with a peripheral hypoechoic halo

and no areas of internal colliquation. Thus, US-guided percutaneous

alcoholization seems to be capable of correct indications in hypoechoic

nodules not exhibiting areas of colliquative necrosis and with negative

antibodies. However, the problem of the dose of alcohol to inject to treat

the nodule thoroughly is still to be debated.

PMID: 8516475 [PubMed - indexed for MEDLINE]

-----------------------------------------------------

2: Gan To Kagaku Ryoho 1999 Oct;26(12):1865-8

[intratumoral ethanol injection therapy using endoscopic video information

system].

Sawa T, Ikoma T, Yoshida T, Kawada M, Azuma K, Murakawa S, Tomita R.

Division of Respiratory Medicine, Gifu Municipal Hospital, Japan.

Bronchoscopic ethanol injection (BEI) therapy for endobronchial malignant

tumor is thought to be an effective modality for airway dilatation and

hemostasis without expensive special equipment. But if ethanol leaks into

the airway, it causes severe coughing and erosion of bronchial wall. Using

endoscopic video information system (EVIS), an assistant operator can

observe an ethanol leak and inject an adequate volume. To evaluate the

efficacy and adverse effect of BEI therapy, we treated 8 patients with

endobronchial malignant tumor using EVIS. Under local anesthesia, a

video-bronchoscope (Olympus BF200 or BF 1T200) was inserted orally, a

transbronchial aspiration cytology (TBAC) needle was inserted via the

biopsy channel, and injections of 0.2 ml of 99% ethanol into the tumor

were repeated. After the tumor degenerated to necrotic tissue, it was

removed with a biopsy forceps, and this maneuver was repeated for the

existing fresh lesion. The total volume of injected ethanol was 4.5 + 1.6

ml (mean + SD). Airway obstruction and atelectasis were relieved in 4

cases, and hemostasis was obtained in 2 cases. In 2 cases, airway

dilatation and hemostasis were not obtained. BEI was more effective in the

patients with polypoid or nodular tumor protruding into the airway lumen.

As for adverse effects, ethanol leaks caused a severe cough in 2 cases,

although they were tolerable and treatment could be continued. BEI therapy

using EVIS was thought to be useful to control airway obstruction by

endobronchial polypoid tumor with good cost-effectiveness and fewer

adverse effects.

PMID: 10560413 [PubMed - indexed for MEDLINE]

moonbeam